| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 26/12/2024 | 19:40 | Edgar (US Regulatory) | Form 40-17G - Fidelity Bond [Rule 17G-1(g)] | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 05/12/2024 | 21:42 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 19/11/2024 | 14:00 | GlobeNewswire Inc. | GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 18/11/2024 | 22:00 | Business Wire | Eagle Capital Growth Fund Declares Year-End Distribution of $0.68 Per Share in Cash | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 29/10/2024 | 13:00 | GlobeNewswire Inc. | Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 22/10/2024 | 14:00 | GlobeNewswire Inc. | Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 03/10/2024 | 14:00 | GlobeNewswire Inc. | GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 29/08/2024 | 20:08 | Edgar (US Regulatory) | Form N-PX - Annual Report of proxy voting record of management investment companies | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 20/08/2024 | 20:02 | Edgar (US Regulatory) | Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public) | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 31/07/2024 | 14:00 | GlobeNewswire Inc. | GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339 | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 29/07/2024 | 14:00 | GlobeNewswire Inc. | Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 01/07/2024 | 12:00 | GlobeNewswire Inc. | Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 18/06/2024 | 13:30 | GlobeNewswire Inc. | Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 17/06/2024 | 10:20 | GlobeNewswire Inc. | Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 18/04/2024 | 15:30 | GlobeNewswire Inc. | Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 04/04/2024 | 10:00 | GlobeNewswire Inc. | Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 07/03/2024 | 17:11 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 06/03/2024 | 18:56 | Edgar (US Regulatory) | Form N-CSR - Certified Shareholder Report | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 14/02/2024 | 09:16 | GlobeNewswire Inc. | Grifols announces positive topline phase 3 fibrinogen clinical trial results | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 13/02/2024 | 21:09 | Edgar (US Regulatory) | Form 5 - Annual statement of changes in beneficial ownership of securities | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 15/11/2023 | 14:00 | GlobeNewswire Inc. | Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 06/11/2023 | 14:00 | GlobeNewswire Inc. | GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023 | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 25/10/2023 | 00:30 | GlobeNewswire Inc. | Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 13/10/2023 | 23:30 | Business Wire | Eagle Capital Growth Fund Declares Year-End Distribution of $0.35 Per Share in Cash | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 02/10/2023 | 20:30 | Edgar (US Regulatory) | Form SC 13D - General statement of acquisition of beneficial ownership | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 02/10/2023 | 20:16 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 15/08/2023 | 21:45 | Edgar (US Regulatory) | Form N-CSRS - Certified Shareholder Report, Semi-Annual | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 01/08/2023 | 14:00 | GlobeNewswire Inc. | Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 12/05/2023 | 19:28 | Edgar (US Regulatory) | Amended Statement of Changes in Beneficial Ownership (4/a) | AMEX:GRF | Eagle Capital Growth Fund Inc |
| 12/05/2023 | 18:43 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | AMEX:GRF | Eagle Capital Growth Fund Inc |